130,297 Shares in Apollomics, Inc. (NASDAQ:APLM) Purchased by Powell Investment Advisors LLC

Powell Investment Advisors LLC purchased a new position in shares of Apollomics, Inc. (NASDAQ:APLM) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 130,297 shares of the company’s stock, valued at approximately $98,000.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on shares of Apollomics from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th.

Apollomics Stock Up 1.3 %

Shares of APLM stock traded up $0.00 during trading hours on Friday, hitting $0.21. The company’s stock had a trading volume of 150,771 shares, compared to its average volume of 312,851. The business has a fifty day moving average of $0.31 and a 200-day moving average of $0.59. Apollomics, Inc. has a twelve month low of $0.18 and a twelve month high of $6.20.

Apollomics Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.